Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cancer drug begins first human tests

NCT ID NCT03833700

Summary

This is an early-stage study testing a new drug called E7386 in people with advanced solid tumors that have spread or returned after previous treatments. The main goal is to find the safest dose and understand side effects in about 70 participants. Researchers will also check if the drug shows any signs of helping control cancer growth.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Eisai Trial Site #1

    Chuo Ku, Tokyo, Japan

  • Eisai Trial Site #2

    Kashiwa, Chiba, Japan

  • Eisai Trial Site #3

    Nagaizumi-cho, Shizuoka, Japan

  • Eisai Trial Site #4

    Fukuoka, Japan

  • Eisai Trial Site #5

    Sapporo, Hokkaido, Japan

  • Eisai Trial Site#6

    Osaka, Japan

  • Eisai Trial Site#7

    Nagoya, Aichi-ken, Japan

  • Eisai Trial Site#8

    Sendai, Miyagi, Japan

Conditions

Explore the condition pages connected to this study.